Contribute Try STAT+ Today

As part of its probe into pharmaceutical industry pricing tactics, a Congressional committee next month plans to hold a hearing and grill AbbVie (ABBV) chief executive officer Richard Gonzalez, whose company at one point faced a subpoena for refusing to cooperate with the investigation.

The move comes after the House Committee on Oversight and Reform last fall released a series of reports detailing how different drug makers engaged in “anticompetitive conduct” to maintain high prices and market share for expensive medicines. The effort reflects concern over rising prescription drug prices and Congressional interest in any illegal strategies companies use to thwart competition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.